{"disease":{"id":"inoperable","name":"inoperable"},"drugs":{"marketed":[{"drug_id":"selumetinib","indication_name":"Neurofibromatosis Type 1 with Symptomatic, Inoperable Plexiform Neurofibromas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Koselugo","generic_name":"selumetinib","company_name":"ASTRAZENECA LP","drug_phase":"marketed","molecular_target":"AP2-associated protein kinase 1","drug_class":"Kinase Inhibitor [EPC]","quality_score":75,"revenue":null,"mechanism":"Selumetinib is an inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK1/2)."},{"drug_id":"metirosine","indication_name":"Management of inoperable pheochromocytoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Demser","generic_name":"metirosine","company_name":"Aton Pharma Vpna","drug_phase":"marketed","molecular_target":"Tyrosine 3-monooxygenase","drug_class":"Catecholamine Synthesis Inhibitor [EPC]","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"selumetinib","indication_name":"Treatment of adult and pediatric patients 1 year of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Koselugo","generic_name":"selumetinib","company_name":"ASTRAZENECA LP","drug_phase":"marketed","molecular_target":"AP2-associated protein kinase 1","drug_class":"Kinase Inhibitor [EPC]","quality_score":75,"revenue":null,"mechanism":"Selumetinib is an inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK1/2)."},{"drug_id":"talc","indication_name":"Inoperable secondary intractable pneumothorax","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sclerosol","generic_name":"TALC","company_name":"Nobelpharma Co., Ltd.","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":13,"revenue":null,"mechanism":""}],"pipeline":[{"drug_id":"dacomitinib-hydrate","indication_name":"EGFR Mutation-positive Inoperable or Reccrent NSCLC","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"dacomitinib hydrate","generic_name":"dacomitinib-hydrate","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"Cyclin-G-associated kinase, Receptor-interacting serine/threonine-protein kinase 2, Receptor-interacting serine/threonine-protein kinase 3","drug_class":"The usual adult starting dosage for oral use is 45mg of dacomitinib hydrate once daily. The dose sho","quality_score":null,"revenue":null,"mechanism":"The usual adult starting dosage for oral use is 45mg of dacomitinib hydrate once daily. The dose sho"}],"offLabel":[],"totalMarketed":4,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT05887011","title":"CRT( Chemo-Radiation Therapy) Patterns and Short-term Outcomes on Unresectable NSCLC and SCLC in Routine Practices in Russia","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT01463891","title":"Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S)","phase":"","overall_status":"COMPLETED","enrollment_count":963,"lead_sponsor_name":"Eisai Co., Ltd.","has_results":false},{"nct_id":"NCT04862663","title":"Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":895,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04305496","title":"Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":818,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT01802632","title":"AZD9291 First Time In Patients Ascending Dose Study","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":603,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT01040312","title":"An Observational Study of CPT-11 Plus Platinum Analogues Regimens and UGT1A1 Genotypes in Solid Tumors","phase":"","overall_status":"COMPLETED","enrollment_count":321,"lead_sponsor_name":"Daiichi Sankyo Co., Ltd.","has_results":false},{"nct_id":"NCT04802759","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":316,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT06942234","title":"Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","has_results":false},{"nct_id":"NCT03911219","title":"Impact of eHealth Monitoring on Overall Survival in Patients With Metastatic NSCLC / Extensive-stage SCLC / Advanced TNBC Under First-line Treatment With Atezolizumab Plus Chemotherapy","phase":"","overall_status":"COMPLETED","enrollment_count":154,"lead_sponsor_name":"iOMEDICO AG","has_results":false},{"nct_id":"NCT03427814","title":"Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":136,"lead_sponsor_name":"BeiGene","has_results":true},{"nct_id":"NCT01757288","title":"Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":98,"lead_sponsor_name":"University of Texas Southwestern Medical Center","has_results":true},{"nct_id":"NCT06190847","title":"Oral Microbiome is Associated With the Response to Chemoradiotherapy in Initial Inoperable Patients With Esophageal Squamous Cell Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":97,"lead_sponsor_name":"Anhui Provincial Hospital","has_results":false},{"nct_id":"NCT04780932","title":"Initial Dual Oral Combination Therapy Versus Standard-of-care Initial Oral Monotherapy Prior to Balloon Pulmonary Angioplasty in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":96,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT05016245","title":"MANDARIN (S6371)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":92,"lead_sponsor_name":"Boston Scientific Corporation","has_results":false},{"nct_id":"NCT06483347","title":"Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":90,"lead_sponsor_name":"Second Affiliated Hospital of Guangzhou Medical University","has_results":false},{"nct_id":"NCT00591838","title":"A Phase I/II Trial of Stereotactic Body Radiation Therapy","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":74,"lead_sponsor_name":"Washington University School of Medicine","has_results":true},{"nct_id":"NCT05833594","title":"Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs for Local Advanced Patients With Inoperable Esophageal Squamous Cell Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Anhui Provincial Hospital","has_results":false},{"nct_id":"NCT05817604","title":"Stereotactic Body Radiotherapy (SBRT) for Medically Inoperable Localised Renal Tumors (SABINA Trial)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Consorci Sanitari de Terrassa","has_results":false},{"nct_id":"NCT03142061","title":"Electrochemotherapy for the Inoperable Vulva Carcinoma","phase":"NA","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"University Hospital Tuebingen","has_results":false},{"nct_id":"NCT03770988","title":"A Trial to Evaluate the Efficacy of Poziotinib, Pan HER Inhibitor in Recurrent/Metastatic Esophageal Cancer (R/M ESCC)","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":49,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT05418543","title":"CH-EUS in Diagnosis of Inoperable Bile Duct Tumors","phase":"NA","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Institutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian Fodor","has_results":false},{"nct_id":"NCT04155541","title":"Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice)","phase":"","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT02157883","title":"Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":39,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT02163733","title":"Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT03600623","title":"Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer","phase":"EARLY_PHASE1","overall_status":"TERMINATED","enrollment_count":25,"lead_sponsor_name":"University of Alabama at Birmingham","has_results":false},{"nct_id":"NCT07311070","title":"Treatment of Basal Cell Carcinoma (BCC) of the Skin, of the Morpheiform, Infiltrative, and Noduloulcerative Types in Inoperable Patients and Not Suitable for Radiotherapy Using Formulated Methylene Blue","phase":"PHASE3","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":20,"lead_sponsor_name":"Daryoush Hamidi Alamdari, PhD","has_results":false},{"nct_id":"NCT07311057","title":"Investigation of Effect of Formulated Methylene Blue on Treatment of Squamous Cell Carcinoma Skin Cancer in Inoperable Patients and Not Suitable for Radiotherapy","phase":"PHASE3","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":20,"lead_sponsor_name":"Daryoush Hamidi Alamdari, PhD","has_results":false},{"nct_id":"NCT04652206","title":"Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients.","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":18,"lead_sponsor_name":"Scandion Oncology A/S","has_results":false},{"nct_id":"NCT01495247","title":"Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":18,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT01933568","title":"Combined CFRT and SABR in Stage II and III NSCLC With Peripheral Tumors Smaller Than 5 cm.","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"The Netherlands Cancer Institute","has_results":false},{"nct_id":"NCT03437200","title":"Combination of Chemoradiation With Immunotherapy in Inoperable œsophageal Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":8,"lead_sponsor_name":"European Organisation for Research and Treatment of Cancer - EORTC","has_results":false},{"nct_id":"NCT03188328","title":"Safety, Tolerability, PK, Dosimetry, MTD and Preliminary Efficacy of Intra-lesionally Injected AvidinOX, Followed by IV Escalating Doses of [177Lu]DOTA-biotin in Pts With Injectable Solid Tumors or Lymphomas","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Alfasigma S.p.A.","has_results":false},{"nct_id":"NCT04685499","title":"Phase 2 Study of OBP-301 (Telomelysin™) in Combination With Pembrolizumab and SBRT in Patients With HNSCC With Inoperable, Recurrent or Progressive Disease","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"Weill Medical College of Cornell University","has_results":true},{"nct_id":"NCT03259633","title":"An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"AstraZeneca","has_results":false}],"total":34},"guidelines":[],"source":"Drug Landscape verified database"}